Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Twin Cities
Tampa Bay news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa Bay
Charlotte news in your inbox
Catch up on the most important stories affecting your hometown with Axios Charlotte
Illustration: Aïda Amer/Axios
New clinical trial data from two experimental coronavirus vaccines — one from Oxford University and AstraZeneca in the United Kingdom, and the other from CanSino Biologics in China — are providing cautious optimism in the race to combat the pandemic.
The big picture: Science has never moved this fast to develop a vaccine. And researchers are still several months away from a clearer idea of whether the leading candidates help people generate robust immune responses to this virus.
Driving the news: The Oxford and CanSino vaccines didn't lead to any severe adverse reactions or hospitalizations, according to the results released yesterday.
- Safety — not efficacy — was the main thing these studies were supposed to be testing. And they performed well enough to move on to further trials.
- Competing candidates from Moderna and Pfizer/BioNTech have also performed well in safety trials.
Yes, but: Future trials will be the ones that tell us whether any of these potential vaccines actually trigger patients' immune systems to respond to the virus.
- In the results released yesterday, Oxford researchers gave their vaccine to 543 people but only tested 35 for "neutralizing antibodies." A separate, nonrandomized group of 10 people got a booster dose of the Oxford vaccine a month after the initial dose.
- Preliminary antibody responses from CanSino's vaccine were "disappointing" to several experts.
"It's a lot of hype," said Paul Offit, a physician and vaccine expert at Children's Hospital of Philadelphia. "It's just trying to read the tea leaves of what will be a large phase three trial."
The bottom line: There are 23 coronavirus vaccines in clinical testing right now, according to the World Health Organization.
- We now have data on the first four, but the studies mostly are confirming that the vaccines aren't severely harmful and that large-scale studies are warranted — not that they definitely work yet.
- "It is good and hopeful news indeed, but we'll only know when the large trials are done," tweeted Robert Califf, a former FDA commissioner under Barack Obama.
Go deeper: Read more about the state of the global race for a vaccine